FLT1 and hereditary clear cell renal cell carcinoma: In addition to FGFRs, these compounds have activity against a wide range of targets, including VEGFR1–3 and platelet-derived growth factor [47, 48], and have demonstrated clinical benefit for the treatment of several tumour types, such as renal cell carcinoma [23, 24], soft tissue sarcoma [49, 50], thyroid cancer [51], metastatic colorectal cancer [52], chronic myeloid leukaemia [53] and NSCLC [54, 55].